Brands of Streptomycin In Kenya:
Carestrep , Careplus Limited
Strepto 1, Crown Healthcare
Streptomycin , Macleods Pharmaceuticals Limited
STREPTOMYCIN MODE OF ACTION
a) Mycobacterium tuberculosis:
b) Non-tuberculosis infections:
Pasteurella pestis (plague),
Francisella tularensis (tularemia),
Calymmatobacterium granulomatis (donovanosis, granuloma inguinale)
H. ducreyi (chancroid),
H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent),
K. pneumoniae pneumonia (concomitantly with another antibacterial agent).
E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections.
Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin)
Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent).
A history of clinically significant hypersensitivity to streptomycin is a contraindication to its use. Clinically significant hypersensitivity to other aminoglycosides may contraindicate the use of streptomycin because of the known cross-sensitivity of patients to drugs in this class.
The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the co-administration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.
The following reactions are common: vestibular ototoxicity (nausea, vomiting, and vertigo); paresthesia of face; rash; fever; urticaria; angioneurotic edema; and eosinophilia.
The following reactions are less frequent: cochlear ototoxicity (deafness); exfoliative dermatitis; anaphylaxis; azotemia; leucopenia; thrombocytopenia; pancytopenia; hemolytic anemia; muscular weakness; and amblyopia.
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, email@example.com or clicking below button:
Clinical | Pharmacokinetic data
Pregnancy Category: D (Evidence of risk)
Routes of Administration: I.V | I.M
Bioavailability: 84% to 88% IM (est.) 0% by mouth
Protein Binding: Not Available
Metabolosim: Not Available
Onset of Action: Not Available
Elimination Half life: 5 to 6 hours
Legal Status | Dosage forms & Strengths
Prescription only medicine
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
Dosage Forms | Strengths: